Miami, FL Clinical Trials Report — July 2026

Miami participants should act quickly if they match a study nearing its enrollment deadline: 68 recruiting trials are expected to close within the next 90 days, including 7 that accept healthy volunteers. Miami currently has 1,309 recruiting trials across 850 research facilities, so people who qualify may have several local options—but enrollment can end before a projected closing date if a study reaches its target.

July brought 15 new trials, down from 32 in May and 32 in June. The six-month pattern has been uneven: 42 new trials opened in February, followed by 30 in March, 28 in April, 35 in May, 32 in June, and 15 in July. The current pipeline remains broad, spanning cancer, respiratory disease, metabolic liver disease, Crohn’s disease, mental health, and pediatric conditions.

Closing-soon studies create the most immediate opportunities

People exploring treatment studies should review closing dates now, particularly those affected by cancer or inflammatory and psychiatric conditions. The largest groups of closing-soon trials in Miami involve:

• Prostate cancer (4 trials)
• Breast cancer (4 trials)
• Atopic dermatitis (3 trials)
• Prostatic neoplasms (2 trials)
• Major depressive disorder (2 trials)
• Schizophrenia (2 trials)
• Cancer generally (2 trials)
• Head and neck cancer (2 trials)
• HER2-negative breast cancer (2 trials)
• Lung cancer (2 trials)

7 of the closing-soon studies accept healthy volunteers. Eligibility may still depend on age, medications, medical history, laboratory results, and the time required for visits. Healthy volunteers who are interested should contact study teams soon rather than waiting for the final listed enrollment date.

Major Phase 2 and Phase 3 studies opening locally

Drug studies dominate July’s new activity with 11 openings, followed by 2 biological studies, 2 device studies, and 1 behavioral study. Industry sponsors account for 11 new trials, while three are classified as other and one as network-sponsored. Several large late-stage studies stand out:

• Amgen is sponsoring NCT07684235, a Phase 3 extension study of maridebart cafraglutide for adults with obesity or overweight. The trial plans to enroll 3,200 participants and evaluates long-term efficacy, safety, and tolerability.
• NCT07679282 is a Phase 4 comparative study of three obstructive sleep apnea approaches: positive airway pressure therapy, a dental device, and atomoxetine-oxybutynin. The study expects 2,400 adults and is sponsored by Sairam Parthasarathy.
• AbbVie sponsors NCT07697456, a Phase 2 study of advanced therapies for adults with moderately to severely active Crohn’s disease or ulcerative colitis. Planned enrollment is 2,000 participants.
• GlaxoSmithKline sponsors NCT07701993, a Phase 3 study of efimosfermin compared with placebo for compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis, or MASH. The study plans to enroll 1,740 adults.
• Expedition Therapeutics is conducting NCT07684820, a Phase 2 study of EXPD-101/FXS7553 for adults with COPD. Participants are randomized to study drug or placebo for 52 weeks, with planned enrollment of 600.
• Karuna Therapeutics, a Bristol Myers Squibb company, sponsors NCT07686263, a Phase 3 relapse-prevention study evaluating KarXT in schizophrenia. The trial expects 472 participants.

Other July openings address artificial intelligence, acute asthma, asthma in children, bone marrow failure syndromes, caregiver burden, COPD exacerbations, diabetic foot ulcers, and MASH. Two new studies concern MASH, making it the most frequent single condition category among the month’s openings.

University of Miami leads local research access

The University of Miami is the city’s largest research hub, with 237 recruiting trials. Its affiliated cancer centers add substantial oncology capacity, while Nicklaus Children’s Hospital provides a major pediatric research presence. The leading Miami facilities are:

• University of Miami (237 trials)
• University of Miami Miller School of Medicine-Sylvester Cancer Center (81 trials)
• Nicklaus Children’s Hospital (57 trials)
• Miami Cancer Institute (49 trials)
• UM Sylvester Comprehensive Cancer Center at Kendall (35 trials)
• Research Site (32 trials)
• Sylvester Comprehensive Cancer Center (29 trials)
• GSK Investigational Site (25 trials)
• University of Miami Miller School of Medicine (17 trials)
• University of Miami Hospital (17 trials)
• Miami Cancer Institute at Baptist Health, Inc. (16 trials)
• Bascom Palmer Eye Institute (15 trials)

These sites give Miami residents several starting points: Sylvester and Miami Cancer Institute for oncology, Nicklaus Children’s Hospital for pediatric studies, Bascom Palmer for eye research, and the University of Miami system for a wide mix of medical conditions. The presence of a GSK investigational site also reflects Miami’s role in industry-sponsored research.

Healthy volunteers and eligibility in July

Only 1 of the 15 new July trials accepts healthy volunteers, but 117 healthy-volunteer studies are recruiting across Miami overall. Four new trials include children, and 14 include older adults. No new study is limited exclusively to female or male participants.

Healthy volunteers should search beyond the July openings because the broader local inventory is much larger. Patients with prostate or breast cancer, atopic dermatitis, respiratory disease, MASH, Crohn’s disease, schizophrenia, or related conditions should prioritize both newly opened studies and trials approaching their enrollment windows.

Nearby Florida alternatives

Participants willing to travel can broaden their search beyond Miami. Other Florida cities with recruiting trials include Tampa (13), Orlando (7), Coral Gables and Hollywood (5 each), Fort Myers and Jacksonville (5 each), Miami Lakes (4), and Fort Lauderdale (3).

As July’s slower pace of new openings continues into the summer, local facilities may provide additional study choices through existing trials. Checking eligibility early and contacting both the University of Miami network and nearby cancer, pediatric, and specialty centers can improve the chance of finding an active study before recruitment closes.